Document:

THIS DEBT SETTLEMENT AND SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT").

NONE OF THE SECURITIES TO WHICH THIS DEBT SETTLEMENT AND SUBSCRIPTION AGREEMENT RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED HEREIN) EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES AND PROVINCIAL LAWS.  IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE 1933 ACT.

DEBT SETTLEMENT AND SUBSCRIPTION AGREEMENT

BETWEEN:

Rafina Innovations Inc. (the "Company"), a company incorporated under the laws of the State of Nevada, with an address for business at 123 West Nye Ln., suite 129, Carson City, Nevada 89706.AND:

Care Providers Co. Inc. (the "Subscriber"), an Ontario corporation with a business address of 22 Sir Modesto Court, Maple, Ontario L6A 0E2, Canada.

WHEREAS:

A. As at March 20, 2019 the Company is indebted to the Subscriber in the amount of One hundred and Twenty Thousand Two Hundred and Thirty One Dollars and Eighty Cents (US$120,231.80) (the "Debt") in respect to certain debt for services rendered up to September 30, 2018 and as evidenced by those certain Assignment Agreements appended as Schedule A hereto,

B. The Subscriber has agreed to accept One Million Three Hundred and Seventy-Four Thousand and Seventy Eight (1,374,078) shares of the Company's common stock at a price of US$0.0875 per share (collectively, the "Shares"), in full and final settlement of the Total Debt (the "Settlement Amount") pursuant to the terms and conditions set forth in this Agreement.

NOW THEREFORE THIS AGREEMENT witnesses that, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

	
1.

	
Interpretation

1.1 In this Agreement, words importing the singular number only shall include the plural and vice versa, words importing gender shall include all genders and words importing persons shall include individuals, corporations, partnerships, associations, trusts, unincorporated organizations, governmental bodies and other legal or business entities of any kind whatsoever.

1.2 Any reference to currency is to the currency of the United States of America unless otherwise indicated.

1

	
2.

	
Acknowledgement of Indebtedness

2.1 The Company and the Subscriber acknowledge and agree that the Company is indebted to the Subscriber in the amount of the Settlement Amount.

	
3.

	
Payment of Indebtedness

3.1 As full and final payment of the Settlement Amount, the Company will on the Closing Date (as defined herein) issue to the Subscriber the Shares, as fully paid and non-assessable, and the Subscriber will accept the Shares as full and final payment of the Settlement Amount.

	
4.

	
Release

4.1 The Subscriber hereby agrees that upon delivery of the Shares by the Company in accordance with the provisions of this Agreement, the Settlement Amount will be fully satisfied and extinguished, and the Subscriber will remise, release and forever discharge the Company and its respective directors, officers, employees, successors, solicitors, agents and assigns from any and all obligations relating to the Settlement Amount.

	
5.

	
Documents Required from Subscriber

5.1 The Subscriber must complete, sign and return to the Company:

	
(a)

	
two (2) executed copies of this Agreement;

5.2 The Subscriber shall complete, sign and return to the Company as soon as possible, on request by the Company, any documents, questionnaires, notices and undertakings as may be required by regulatory authorities, the OTC Bulletin Board, stock exchanges and applicable law.

	
6.

	
Closing

6.1 Closing of the offering of the Shares (the "Closing") shall occur on such date as may be determined by the Company and the Subscriber (the "Closing Date").

	
7.

	
Acknowledgements of Subscriber

7.1 The Subscriber acknowledges and agrees that:

	
(a)

	
none of the Shares have been or will be registered under the Securities Act of 1933 (the "1933 Act"), or under any state securities or "blue sky" laws of any state of the United States, and, unless so registered, may not be offered or sold in the United States or, directly or indirectly, to U.S. Persons, as that term is defined in Regulation S under the 1933 Act ("Regulation S"), except in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the 1933 Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act and in each case only in accordance with applicable securities laws;

	
(b)

	
the Company has not undertaken, and will have no obligation, to register any of the Shares under the 1933 Act or any other applicable securities legislation;

	
(c)

	
the Subscriber has received and carefully read this Agreement;

	
(d)

	
the decision to execute this Agreement and acquire the Shares hereunder has not been based upon any oral or written representation as to fact or otherwise made by or on behalf of the Company and such decision is based entirely upon a review of any public information which has been filed by the Company with the Securities and Exchange Commission ("SEC") in compliance, or intended compliance, with applicable securities legislation;

	
(e)

	
the Subscriber and the Subscriber's advisor(s) have had a reasonable opportunity to ask questions of and receive answers from the Company in connection with the issuance of the Shares hereunder, and to obtain additional information, to the extent possessed or obtainable by the Company without unreasonable effort or expense;

2

	
(f)

	
the books and records of the Company were available upon reasonable notice for inspection, subject to certain confidentiality restrictions, by the Subscriber during reasonable business hours at its principal place of business and that all documents, records and books in connection with the issuance of the Shares hereunder have been made available for inspection by the Subscriber and the Subscriber's attorney and/or advisor(s);

	
(g)

	
the Company is entitled to rely on the representations and warranties and the statements and answers of the Subscriber contained in this Agreement and the Questionnaire and the Subscriber will hold harmless the Company from any loss or damage it or they may suffer as a result of the Subscriber's failure to correctly complete this Agreement or the Questionnaire;

	
(h)

	
the Subscriber will indemnify and hold harmless the Company and, where applicable, its respective directors, officers, employees, agents, advisors and shareholders from and against any and all loss, liability, claim, damage and expense whatsoever (including, but not limited to, any and all fees, costs and expenses whatsoever reasonably incurred in investigating, preparing or defending against any claim, lawsuit, administrative proceeding or investigation whether commenced or threatened) arising out of or based upon any representation or warranty of the Subscriber contained herein, in the Questionnaire or in any document furnished by the Subscriber to the Company in connection herewith being untrue in any material respect or any breach or failure by the Subscriber to comply with any covenant or agreement made by the Subscriber to the Company in connection therewith;

	
(i)

	
upon the issuance thereof, and until such time as the same is no longer required under the applicable securities laws and regulations, the certificates representing any of the Shares will bear a legend in substantially the following form:

THESE SECURITIES WERE ISSUED IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT").

NONE OF THE SECURITIES TO WHICH THIS CERTIFICATE RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD IN THE UNITED STATES OR, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PURSUANT TO AN EXEMPTION  FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN ACCORDANCE WITH THE 1933 ACT.

	
(j)

	
the Subscriber has been advised to consult the Subscriber's own legal, tax and other advisors with respect to the merits and risks of an investment in the Shares and with respect to applicable resale restrictions, and it is solely responsible (and the Company is not in any way responsible) for compliance with:

	
(i)

	
any applicable laws of the jurisdiction in which the Subscriber is resident in connection with the distribution of any of the Shares hereunder, and

	
(ii)

	
applicable resale restrictions;

3

	
(k)

	
none of the Shares are listed on any stock exchange or automated dealer quotation system and no representation has been made to the Subscriber that any of the Shares will become listed on any stock exchange or automated dealer quotation system, except that currently certain market makers make market in the common shares of the Company on the OTC Bulletin Board;

	
(l)

	
none of the Shares may be offered or sold to a U.S. Person or for the account or benefit of a U.S. Person (other than a distributor) prior to the end of the Distribution Compliance Period (as defined herein);

	
(m)

	
neither the SEC nor any other securities commission or similar regulatory authority has reviewed or passed on the merits of the Shares or has reviewed any documents in connection with the sale of the Shares hereunder;

	
(n)

	
there is no government or other insurance covering any of the Shares;

	
(o)

	
the issuance and sale of the Shares to the Subscriber will not be completed if it would be unlawful or if, in the discretion of the Company acting reasonably, it is not in the best interests of the Company;

	
(p)

	
the statutory and regulatory basis for the exemption claimed for the offer and issuance of the Shares, although in technical compliance with Regulation S, would not be available if the offering is part of a plan or scheme to evade the registration provisions of the 1933 Act; and

	
(q)

	
this Agreement is not enforceable by the Subscriber unless it has been accepted by the Company.

	
8.

	
Representations, Warranties and Covenants of the Subscriber

8.1 The Subscriber hereby represents and warrants to and covenants with the Company (which representations, warranties and covenants shall survive the Closing) that:

	
(a)

	
the Subscriber is not a U.S. Person;

	
(b)

	
the Subscriber is not acquiring the Shares for the account or benefit of, directly or indirectly, any U.S. Person;

	
(c)

	
the Subscriber is resident in the jurisdiction set out under the heading "Name and Address of Subscriber" on the signature page of this Agreement;

	
(d)

	
the sale of the Shares to the Subscriber as contemplated by the delivery of this Agreement, the acceptance of it by the Company and the issuance of the Shares to the Subscriber complies with all applicable laws of the Subscriber's jurisdiction of residence or domicile;

	
(e)

	
the Subscriber:

	
(i)

	
is knowledgeable of, or has been independently advised as to, the applicable securities laws of the securities regulators having application in the jurisdiction in which the Subscriber is resident (the "International Jurisdiction") which would apply to the acquisition of the Shares;

	
(ii)

	
the Subscriber is acquiring the Shares pursuant to exemptions from prospectus or equivalent requirements under applicable securities laws or, if such is not applicable, the Subscriber is permitted to acquire the Shares under the applicable securities laws of the securities regulators in the International Jurisdiction without the need to rely on any exemptions;

4

	
(iii)

	
the applicable securities laws of the authorities in the International Jurisdiction do not require the Company to make any filings or seek any approvals of any kind whatsoever from any securities regulator of any kind whatsoever in the International Jurisdiction in connection with the issue and sale or resale of the Shares; and

	
(iv)

	
the acquisition of the Shares by the Subscriber does not trigger:

	
A.

	
any obligation to prepare and file a prospectus or similar document, or any other report with respect to such acquisition in the International Jurisdiction; or

	
B.

	
any continuous disclosure reporting obligation of the Company in the International Jurisdiction; and

	
(v)

	
the Subscriber will, if requested by the Company, deliver to the Company a certificate or opinion of local counsel from the International Jurisdiction which will confirm the matters referred to in subparagraphs (ii), (iii) and (iv) above to the satisfaction of the Company, acting reasonably;

	
(f)

	
the Subscriber is acquiring the Shares as principal for investment purposes only and not with a view to resale or distribution and, in particular, the Subscriber has no intention to distribute, either directly or indirectly, any of the Shares in the United States or to U.S. Persons;

	
(g)

	
the Subscriber is outside the United States when receiving and executing this Agreement;

	
(h)

	
the Subscriber is aware that an investment in the Company is speculative and involves certain risks, including the possible loss of the entire investment;

	
(i)

	
the Subscriber has made an independent examination and investigation of an investment in the Shares and the Company and has depended on the advice of its legal and financial advisors and agrees that the Company will not be responsible in any way whatsoever for the Subscriber's decision to invest in the Shares and the Company;

	
(j)

	
the Subscriber (i) has adequate net worth and means of providing for its current financial needs and possible personal contingencies, (ii) has no need for liquidity in this investment, and (iii) is able to bear the economic risks of an investment in the Shares for an indefinite period of time;

	
(k)

	
all information contained in the Questionnaire is complete and accurate and may be relied upon by the Company, and the Subscriber will notify the Company immediately of any material change in any such information occurring prior to the closing of the acquisition of the Shares;

	
(l)

	
the Subscriber understands and agrees that the Company and others will rely upon the truth and accuracy of the acknowledgements, representations and agreements contained in this Agreement and the Questionnaire and agrees that if any of such acknowledgements, representations and agreements are no longer accurate or have been breached, it shall promptly notify the Company;

	
(m)

	
the Subscriber has the legal capacity and competence to enter into and execute this Agreement and to take all actions required pursuant hereto;

	
(n)

	
the Subscriber has duly executed and delivered this Agreement and it constitutes a valid and binding agreement of the Subscriber enforceable against the Subscriber in accordance with its terms;

	
(o)

	
the Subscriber is not an underwriter of, or dealer in, the common shares of the Company, nor is the Subscriber participating, pursuant to a contractual agreement or otherwise, in the distribution of the Shares;

	
(p)

	
the Subscriber understands and agrees that none of the Shares have been registered under the 1933 Act, or under any state securities or "blue sky" laws of any state of the United States, and, unless so registered, may not be offered or sold in the United States or, directly or indirectly, to U.S. Persons except in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the 1933 Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act and in each case only in accordance with applicable state and provincial securities laws;

5

	
(q)

	
the Subscriber understands and agrees that offers and sales of any of the Shares prior to the expiration of the applicable period specified by Regulations (such period hereinafter referred to as the "Distribution Compliance Period") shall only be made in compliance with the safe harbor provisions set forth in Regulation S, pursuant to the registration provisions of the 1933 Act or an exemption therefrom, and that all offers and sales after the Distribution Compliance Period shall be made only in compliance with the registration provisions of the 1933 Act or an exemption therefrom and in each case only in accordance with applicable state, provincial and foreign securities laws;

	
(r)

	
the Subscriber understands and agrees that the Company will refuse to register any transfer of the Shares not made in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the 1933 Act or pursuant to an available exemption from the registration requirements of the 1933 Act;

	
(s)

	
the Subscriber has the requisite knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of the investment in the Shares and the Company;

	
(t)

	
the Subscriber acknowledges that it has not acquired the Shares as a result of, and will not itself engage in, any "directed selling efforts" (as defined in Regulation S under the 1933 Act) in the United States in respect of any of the Shares which would include any activities undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United States for the resale of any of the Shares; provided, however, that the Subscriber may sell or otherwise dispose of any of the Shares pursuant to registration of any of the Shares pursuant to the 1933 Act and any applicable state securities laws or under an exemption from such registration requirements and as otherwise provided herein; and

	
(u)

	
no person has made to the Subscriber any written or oral representations,

	
(i)

	
that any person will resell or repurchase any of the Shares,

	
(ii)

	
as to the future price or value of any of the Shares, or

	
(iii)

	
that any of the Shares will be listed and posted for trading on any stock exchange or automated dealer quotation system or that application has been made to list and post any of the Shares of the Company on any stock exchange or automated dealer quotation system.

8.2 In this Agreement, the term "U.S. Person" shall have the meaning ascribed thereto in Regulation S.

	
9.

	
Acknowledgement and Waiver

9.1 The Subscriber has acknowledged that the decision to acquire the Shares was solely made on the basis of publicly available information.  The Subscriber hereby waives, to the fullest extent permitted by law, any rights of withdrawal, rescission or compensation for damages to which the Subscriber might be entitled in connection with the distribution of any of the Shares.

	
10.

	
Representations and Warranties will be Relied Upon by the Company

10.1 The Subscriber acknowledges that the representations and warranties contained herein and are made by it with the intention that such representations and warranties may be relied upon by the Company and its legal counsel in determining the Subscriber's eligibility to acquire the Shares under applicable securities legislation, or (if applicable) the eligibility of others on whose behalf it is contracting hereunder to acquire the Shares under applicable securities legislation.  The Subscriber further agrees that by accepting delivery of the certificates representing the Shares on the Closing Date, it will be representing and warranting that the representations and warranties contained herein and are true and correct as at the Closing Date with the same force and effect as if they had been made by the Subscriber on the Closing Date and that they will survive the acquisition by the Subscriber of Shares and will continue in full force and effect notwithstanding any subsequent disposition by the Subscriber of such Shares.

	
11.

	
Resale Restrictions

11.1 The Subscriber acknowledges that any resale of the Securities will be subject to resale restrictions contained in the securities legislation applicable to the Subscriber or proposed transferee.  The Subscriber acknowledges that the Shares have not been registered under the 1933 Act of the securities laws of any state of the United States.  The Shares may not be offered or sold in the United States unless registered in accordance with United States federal securities laws and all applicable state and provincial securities laws or exemptions from such registration requirements are available.

11.2 The Subscriber acknowledges that restrictions on the transfer, sale or other subsequent disposition of the Shares by the Subscriber may be imposed by securities laws in addition to any restrictions referred to in Section 11.1 above, and, in particular, the Subscriber acknowledges and agrees that none of the Shares may be offered or sold to a U.S. Person or for the account or benefit of a U.S. Person (other than a distributor) prior to the end of the Distribution Compliance Period.

6

	
12.

	
Legending and Registration of Subject Shares

12.1 The Subscriber hereby acknowledges that a legend may be placed on the certificates representing any of the Shares to the effect that the Shares represented by such certificates are subject to a hold period and may not be traded until the expiry of such hold period except as permitted by applicable securities legislation.

12.2 The Subscriber hereby acknowledges and agrees to the Company making a notation on its records or giving instructions to the registrar and transfer agent of the Company in order to implement the restrictions on transfer set forth and described in this Agreement.

	
13.

	
Collection of Personal Information

13.1 The Subscriber acknowledges and consents to the fact that the Company is collecting the Subscriber's personal information for the purpose of fulfilling this Agreement and completing this offering.  The Subscriber's personal information (and, if applicable, the personal information of those on whose behalf the Subscriber is contracting hereunder) may be disclosed by the Company to (a) stock exchanges or securities regulatory authorities, (b) the Company's registrar and transfer agent, and (c) any of the other parties involved in this offering, including legal counsel, and may be included in record books in connection with this offering.  By executing this Agreement, the Subscriber is deemed to be consenting to the foregoing collection, use and disclosure of the Subscriber's personal information (and, if applicable, the personal information of those on whose behalf the Subscriber is contracting hereunder) and to the retention of such personal information for as long as permitted or required by law or business practice.  Notwithstanding that the Subscriber may be acquiring Shares as agent on behalf of an undisclosed principal, the Subscriber agrees to provide, on request, particulars as to the identity of such undisclosed principal as may be required by the Company in order to comply with the foregoing.

	
14.

	
Costs

14.1 The Subscriber acknowledges and agrees that all costs and expenses incurred by the Subscriber (including any fees and disbursements of any special counsel retained by the Subscriber) relating to the acquisition of the Shares shall be borne by the Subscriber.

	
15.

	
Governing Law

15.1 This Agreement is governed exclusively by the laws of the State of Nevada and the federal laws applicable therein and the Subscriber hereby exclusively attorns to the jurisdiction of the courts of the State of Nevada.

7

	
16.

	
Survival

16.1 This Agreement, including without limitation the representations, warranties and covenants contained herein, shall survive and continue in full force and effect and be binding upon the parties hereto notwithstanding the completion of the acquisition of the Shares by the Subscriber pursuant hereto.

	
17.

	
Assignment

17.1 This Agreement is not transferable or assignable.

	
18.

	
Execution

18.1 The Company shall be entitled to rely on delivery by facsimile machine of an executed copy of this Agreement and acceptance by the Company of such facsimile copy shall be equally effective to create a valid and binding agreement between the Subscriber and the Company in accordance with the terms hereof.

	
19.

	
Severability

19.1 The invalidity or unenforceability of any particular provision of this Agreement shall not affect or limit the validity or enforceability of the remaining provisions of this Agreement.

8

	
20.

	
Entire Agreement

20.1 Except as expressly provided in this Agreement and in the agreements, instruments and other documents contemplated or provided for herein, this Agreement contains the entire agreement between the parties with respect to the sale of the Shares and there are no other terms, conditions, representations or warranties, whether expressed, implied, oral or written, by statute or common law, by the Company or by anyone else.

	
21.

	
Notices

21.1 All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication.  Notices to the Subscriber shall be directed to the address on page 9 hereto and notices to the Company shall be directed to the Company's in-house corporate counsel, Nikolaos Kardaras at 123 West Nye Ln., suite 129, Carson City, Nevada 89706.

	
22.

	
Counterparts

22.1 This Agreement may be executed in any number of counterparts, each of which, when so executed and delivered, shall constitute an original and all of which together shall constitute one instrument. Delivery of an executed counterpart of this Agreement by electronic means, including by facsimile transmission or by electronic delivery in portable document format (".pdf"), shall be equally effective as delivery of a manually executed counterpart hereof.  The Parties acknowledge and agree that in any legal proceedings between them respecting or in any way relating to this Agreement, each waives the right to raise any defense based on the execution hereof in counterparts or the delivery of such executed counterparts by electronic means.

IN WITNESS WHEREOF the Subscriber has duly executed this Agreement as of the date first above mentioned.

DELIVERY INSTRUCTIONS

	
1.

	
Delivery - please deliver the certificates to:

  

  

2. The undersigned hereby acknowledges that it will deliver to the Company all such additional completed forms in respect of the Subscriber's acquisition of the Shares as may be required for filing with the appropriate securities commissions and regulatory authorities.

Care Providers Co. Inc. 

 (Name of Subscriber – Please type or print)

 /s/Ilya Aharon 

   

(Signature and, if applicable, Office)

 922 Sir Modesto Court 

(Address of Subscriber)

Maple Ontario L6A 0E2 

(City, State or Province, Postal Code of Subscriber)

Canada 

 (Country of Subscriber)

9

ACCEPTANCE

The above-mentioned Agreement in respect of the Shares is hereby accepted by Rafina Innovations Inc.

DATED at Athens, Greece effective as of the 5th Day of April, 2019.

Rafina Innovations Inc.

Per:        /s/Paraskevi Pilarinou  

 Authorized Signatory

Paraskevi ("Vicky") Pilarinou

CFO and Director

10EXIBIT 10.39(a)

    

    

    CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND (II)
        WOULD BE COMPETIVELY HARMFUL IF PUBLICY DISCLOSED. BRACKETS HAVE BEEN INSERTED WHERE OMITTEED INFORMATION WOULD OTHERWISE APPEAR.

    

    

  

  AMENDMENT NO. 1

  TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT

  

  

  This Amendment No. 1 to the Veto Cell Production and Clinical Trial Program Agreement (“Amendment”) is made and
      entered into as of April 4, 2019 by and between Cell Source Limited (“Cell Source”) and The University of Texas M.D. Anderson Cancer Center (“MD Anderson”), a member institution of The University of Texas System (“System”).

  

  

  RECITALS

  

  

  
    
      	A.	
              Cell Source and MD Anderson entered into a Veto Cell Production and Clinical Trial Program Agreement dated February 19, 2019 (the “Agreement”).

            

    

  

  

  

  
    
      	B.	
              Cell Source and MD Anderson wish to amend the terms of the Agreement as set forth below.

            

    

  

  

  

  NOW, THEREFORE, it is hereby agreed as follows:

  

  

  
    
      	1.	
              Exhibit B of the Agreement shall be revised in its entirety with the attached Amended Exhibit B.

            

    

  

  

  

  
    
      	2.	
              Except as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall continue in full force and effect as
                  provided therein.

            

    

  

  

  

  IN WITNESS WHEREOF, Cell Source and MD Anderson have entered into this Amendment effective as of the date first
      set forth above.

  

  

  	
          CELL SOURCE

        	 	
          THE UNIVERSITY OF TEXAS

        	 
	 

        	 	M.D. ANDERSON CANCER CENTER	 
	 	 	 	 
	 	 	 	 
	
          By /s/ Itamar Shimrat

        	 	
          By /s/ Nyma Shah

        	 
	
          Itamar Shimrat

        	 	
          Name:  Nyma Shah

        	 
	
          Chief Executive Officer

        	 	
          Title:  Director, Research Funding Programs

        	 
	 	 	 	 
	
          Date: April 4, 2019

        	 	
          Date: April 19, 2019

        	 
	 	 	 	 
	 	 	 	 
	 	 	
          Read & Understood:

        	 
	 	 	 	 
	 	 	 	 
	 	 	
          /s/ Richard Champlin

        	 
	 	 	
          Dr. Richard Champlin

        	 
	 	 	
          Principal Investigator

           

            

        	 

  
    
      

    
      EXIBIT 10.39(a)

      

      

      CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND
          (II) WOULD BE COMPETIVELY HARMFUL IF PUBLICY DISCLOSED. BRACKETS HAVE BEEN INSERTED WHERE OMITTEED INFORMATION WOULD OTHERWISE APPEAR.

      

      

    

  

  Amended Exhibit B

  

  

  PAYMENT
          PLAN

  

  

  

  

  

  

  Payment Terms

  

  

  Payments shall be made by Electronic Funds Transfer via the Automated Clearing House (ACH), which is MD Anderson’s
      preferred method to receive payments, or by wire or check.  With each payment, Sponsor shall provide the appropriate MD Anderson Research Contracts Tracking Number (RCTS # 56497 and MD Anderson’s invoice number (GRNXXXXXX) if applicable.  To minimize
      any delays in receiving and applying payments, Sponsor will provide the following information via email transmission to GC_Payments@mdanderson.org at the time
          payment is issued to MD Anderson:

  

  

  
    	
            ·

          	
            the name of the bank submitting the payment,

          

  

  
    	
            ·

          	
            RCTS number : [     ]

          

  

  
    	
            ·

          	
            amount of the payment,

          

  

  
    	
            ·

          	
            MD Anderson Principal Investigator Richard Champlin MD

          

  

  
    	
            ·

          	
            Sponsor contact name or email regarding Payments

          

  

  
    	
            ·

          	
            Sponsor Protocol number 2018-0221

          

  

  

  

  Electronic Payments (ACH and Wire) 

  Bank Name:                       JP Morgan Chase Bank, N.A

  Bank Address:                  910 Travis

                                              Houston, Texas 77002

  Account Name:                Univ of Texas MD Anderson Cancer Center

  Account Number:            [          ]

  Domestic Banks:              ABA Routing Number: 111000614 (ACH) 021000021 (Wire)

  Internal Swift:                   CHASUS33 (international)

  

  

  Checks should be mailed to:

  

  

  The University of Texas

  MD Anderson Cancer Center

  Attn: Grants and Contracts RCTS # 56497

  P.O. BOX 4266

  Houston, Texas 77210-4266

  

  

  If Sponsor issues a payment to MD Anderson that combines payments for multiple studies, Sponsor will provide a detail
      listing including MD Anderson Principal Investigator and the amount of payment for each study via email transmission to GC_Payments@mdanderson.org upon issuing payment to MD Anderson.

   

      

  
    
      

    
      EXIBIT 10.39(a)

      

      

      CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND
          (II) WOULD BE COMPETIVELY HARMFUL IF PUBLICY DISCLOSED. BRACKETS HAVE BEEN INSERTED WHERE OMITTEED INFORMATION WOULD OTHERWISE APPEAR.

      

      

    

  

  

  

  	
          EXHIBIT B- BUDGET

           

          Funding Agency:

        	
           

           

          Cell Source Limited

        	 
	
          Principal Investigator:

        	
          Champlin, Richard

        	 
	
          Title:

        	
          Role of Veto Cells in Haploidentical Transplantation for Myeloma

        	 
	
          Project Dates:

        	
          TBD

        	 
	
          Protocol(s)

        	
          2018-0221

        	
          3% increase

        
	
          Total Patients

        	
          [_____]

        	 
	
           

          *

        	
           

        	 

  
    

    

  

  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
           Year 1

        	 	 	
          Year 2

        	 	 	 	 
	
          Personnel

        	 	 	
          Base Salary

        	 	 	
          Cal Mths.

        	 	 	
          Effort

        	 	 	
          Salary

        	 	 	
          Fringe

        	 	 	
          Total

        	 	 	
          Total

        	 	 	
          Grand Total

        	 
	 	
          [           

            

        	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	
          [[           

        	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        
	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        
	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        
	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        
	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        	 	 	[           	
          ]

        
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Salary Total

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
          $

        	[            

        	 ]

        	 	
          $

        	[           	
          ]

        	 	 	[           	
          ]

        
	
           

          Equipment

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
          $

        	
          --

        	 	 	
          $

        	
          --

        	 	 	 	
          --

        	 
	
          Consultant Costs

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
          $

        	 	 	 	 	 	 	 	$	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Total

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
          $

        	
          --

        	 	 	
          $

        	
          --

        	 	 	
          $

        	
          --

        	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Supplies

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Travel

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Total

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

  
    

    

    Patient Care Costs

    CTRC Admin Fee

    

    

    Other Direct Costs

    

    

  

  	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]***

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	[           	
          ]

        	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	 	 	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	
          Total

        	 	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	       
	
          Direct Costs

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	      
	
          Indirect Costs [ ]%

        	 	 	
          $

        	 	 	
          [________]

        	 	
          $

        	 	 	
          [_________]

        	 	
          $

        	 	 	
          [_________]

        
	
          Total Costs

        	 	 	 	 	 	
          $1,103,978.68

        	 	 	 	 	
          $811,249.33

        	 	 	 	 	
          $1,915,228.01

        
	 	 	
          ***[       ].

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]